Vendin S.L. made a bid to acquire Biosearch, S.A. (BME:BIO) from Groupe Lactalis S.A., Pescaderías Coruñesas and others for approximately €130 million on February 15, 2021. Under the terms of transaction, Vendin will acquire 56.7 million shares for €2.2 per share. Groupe Lactalis has irrevocably committed to accept the offer in relation to its 17.02 million shares representing 29.50%. Vendin has sufficient equity and debt commitments to pay the total consideration. Offer is subject to being irrevocably accepted by shareholders holding shares representing at least 50% plus one share of the share capital, subject to obtaining all the antitrust authorizations. As on March 23, 2021, National Commission of Markets and Competition approved the transaction. Offeror intends to exercise the squeeze-out right over Biosearch’s shares at the price of the offer which shall be adjusted, as the case may be, in the event that any distribution of dividends or any distribution to shareholder. As of April 30, 2021, Council of Ministers approved the transaction. As of May 27, 2021, Comisión Nacional del Mercado de Valores (CNMV) approved the transaction. As on June 11, 2021, Pescaderías Coruñesas expressed its intention of not accepting the offer for 9.01% stake it owns in Biosearch, S.A. As of May 31, 2021, the acceptance period for the bid will be from May 31, 2021 to June 29, 2021, inclusive. On June 8, 2021, the Board of Biosearch approved the transaction. As on June 28, 2021, Pescaderías Coruñesas decided to accept the offer for 9.01% stake it owns in Biosearch, S.A. BNP Paribas SA (ENXTPA:BNP) acted as financial advisor to Kerry Group plc, parent of Vendin S.L. Vendin S.L. completed the acquisition of Biosearch, S.A. (BME:BIO) from Groupe Lactalis S.A., Pescaderías Coruñesas and others on July 5, 2021. Kerry acquired 90.33% of the outstanding shares and will exercise the right of forced sale of 9.67% of Biosearch for the same consideration offered in the offer, that is, €2.20 for each share, setting July 27, 2021 as the transaction date. Kerry will request the National Securities Market Commission (CNMV) to agree to suspend the trading of Biosearch shares on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges after the closing of the stock market of July 15, 2021, and that the listing of the remaining shares will remain suspended until the definitive exclusion of negotiation takes place. The delisting of the Biosearch shares will be effective when the forced sale transaction has been settled. The acquisition of the shares tendered will be settled on July 8, 2021.